Is Aadi Bioscience, Inc. (AADI) a Buy, Sell, or Hold?
NASDAQ : AADI
Aadi Bioscience, Inc.
$2.05 USD
-$0.05 (-2.38%)
- Volume
- 62.61K
- Average Volume
- 200.71K
- Market Capitalization
- $94.89M
- P/E Ratio
- -1.49
- Dividend Yield
- 0.00%
- Price Target
- $1.63
- Year High
- $3.81
- Year Low
- $1.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.36
Company Overview
NASDAQ
David J. Lennon
Biotechnology
Healthcare
AADI
53
US
USD
Liquidity Metrics
0.00
11.36
11.36
3.15
0.00
Sales & Valuation
$7.14M
0.00
1.22
-9.69
-0.14
Profitability
-$0.0333
-$20.6M
0.00%
0.00%
-79.63%
-91.02%
P/E Metrics
-1.49
0.00
0.00
Analyst Price Target & Rating
$1.63
$1.75
$1.50
0/5
6 Analysts
26.15%
Financial Health Scores
-1.00
1/9
$114.49M
$127.23M
$11.06M
-$119.5M
Key Metrics (TTM)
$60.1M
0.00
-0.51
11.36
-79.63%
-105.62%
-81.59%
-10.32%
0 days
Company Executives
| Name | Title |
|---|---|
| Neil Desai | Founder & Director |
| Scott Giacobello | Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications |
| Bryan Ball | Chief Technical Operations Officer |
| Raymond G. Steitz | Senior Vice President of Human Resources & Chief Human Resources Officer |
| Stephen Rodin | Senior Vice President of Legal & General Counsel |
| David Dornan | Chief Scientific Officer |
| David J. Lennon | President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Aadi Bioscience, Inc. (NASDAQ:AADI) Stock
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California. ...
Frequently Asked Questions
-
What is the current Aadi Bioscience, Inc. (AADI) stock price?
-
Aadi Bioscience, Inc.(NASDAQ:AADI) stock price is $2.05 in the last trading session. During the trading session, AADI stock reached the peak price of $3.812 while $1.21 was the lowest point it dropped to. The percentage change in AADI stock occurred in the recent session was --2.38% while the dollar amount for the price change in AADI stock was -$0.05.
-
AADI's industry and sector of operation?
-
The NASDAQ listed AADI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AADI?
-
Neil Desai | Founder & Director
Scott Giacobello | Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications
Bryan Ball | Chief Technical Operations Officer
Raymond G. Steitz | Senior Vice President of Human Resources & Chief Human Resources Officer
Stephen Rodin | Senior Vice President of Legal & General Counsel -
How many employees does AADI have?
-
Number of AADI employees currently stands at 53. AADI operates from 17383 Sunset Boulevard, Pacific Palisades, CA 90272, US.
-
Link for AADI official website?
-
Official Website of AADI is: https://aadibio.com
-
How do I contact AADI?
-
AADI could be contacted at phone #424 473 8055 and can also be accessed through its website. AADI operates from 17383 Sunset Boulevard, Pacific Palisades, CA 90272, US.
-
How many shares of AADI are traded daily?
-
The average number of AADI shares traded daily for last 3 months was 200.71K.
-
What is the market cap of AADI currently?
-
The market value of AADI currently stands at $94.89M with its latest stock price at $2.05